THE WHAT? Novo Nordisk has begun broad US distribution of Wegovy capsule, the primary oral GLP-1 therapy authorized for power weight administration in adults with weight problems or obese with associated medical situations.
THE DETAILS The once-daily oral formulation of semaglutide obtained FDA approval on December 22, 2025 and is now out there by greater than 70,000 US pharmacies, together with CVS and Costco, in addition to chosen telehealth platforms and on-line pharmacy providers.
Scientific information from the Section III OASIS 4 trial confirmed common weight lack of roughly 17 p.c at 64 weeks amongst sufferers who remained on therapy, in contrast with round 3 p.c for placebo. When together with all trial contributors no matter therapy adherence, common weight reduction was roughly 14 p.c, versus 2 p.c for placebo.
The beginning dose of 1.5 mg is being supplied by way of a self-pay programme at US$149 monthly, with tiered pricing for larger doses. Novo Nordisk stated the security profile noticed in OASIS 4 was according to earlier injectable Wegovy trials, with gastrointestinal results among the many mostly reported hostile reactions.
THE WHY? The launch marks a major growth of the GLP-1 market past injectable therapies, doubtlessly broadening entry and adoption amongst sufferers reluctant to make use of injections. For shopper well being, vitamin and beauty-adjacent sectors, the rollout highlights the rising convergence of pharmaceutical weight administration, wellness and long-term way of life intervention, as demand for weight problems therapies accelerates within the US. Elevated availability and decrease entry pricing may additional intensify competitors throughout the quickly increasing weight-loss class.
Supply: Novo Nordisk
